Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carvana Co (CVNA) vs 10X Genomics Inc (TXG) Price & Performance

Carvana CoTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Carvana Co vs 10X Genomics Inc — how do they compare? Carvana Co trades at $70.58 (market cap $79.17B), while 10X Genomics Inc trades at $58.12 (market cap $7.61B). The key difference: Carvana Co is far larger — about 10.4× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.

CVNATXG
Market Cap
$79.17B$7.61B
Sector
Consumer CyclicalHealth
52-Week High
$95.69$58.57
52-Week Low
$56.27$11.34
Enterprise Value
$81.65B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carvana Co

Carvana (CVNA) trades at $74.20, up 4.73% today, with strong recent earnings beats and bullish technical signals. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, while net income reached a record $513 million. The stock faces valuation concerns with a P/E of 38.1 and EV/EBITDA of 575.03, but positive cash flow trends and analyst consensus support growth prospects.

The outlook remains optimistic due to robust unit growth and AI-driven cost efficiencies, though risks include profit margin compression and high debt levels. With a consensus price target of $87.18, upside potential exists if execution continues, but investors should monitor competitive pressures and macroeconomic headwinds.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About Carvana Co

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.

Read more on CVNA

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG